Investors

• June 17, 2013
  Roche's Avastin approved in Japan for treatment of the most aggressive form of brain cancer
• June 14, 2013
  Anti-Cancer Agent, Herceptin Obtained Approval for Dosage and Administration for Postoperative Adjuvant Chemotherapy in Breast Cancer in Japan
• June 14, 2013
  Anti-Cancer Agent Tarceva, Obtained Approval for Additional Indication (First Line Therapy) of Non-Small Cell Lung Cancer with EGFR Mutations in Japan

• All Investor Updates

Roche maintains open and honest relationships with our shareholders, prospective investors and the wider investment community. The role of Investor Relations is to manage these relationships efficiently, transparently and consistently in accordance with company polices and relevant securities rules and laws. more

Basel, Switzerland, March 05, 2013
Annual General Meeting

Subject to appoval by the AGM, planned dividend dates are as follows:
March 07, 2013
Ex-dividend date

March 11, 2013
Record date

March 12, 2013
Dividend payment date

Basel, Switzerland, April 11, 2013
1st Quarter Conference Call

Basel, Switzerland, July 25, 2013
Half Year Results

Basel, Switzerland, October 17, 2013
3rd Quarter Conference Call